Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Randomized Study to Determine Whether Use of Rhopress Can Ameliorate Corneal Edema Associated With Fuchs Dystrophy

Next Previous
Trial Profile

Prospective Randomized Study to Determine Whether Use of Rhopress Can Ameliorate Corneal Edema Associated With Fuchs Dystrophy

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 20 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Netarsudil (Primary)
  • Indications Fuchs' endothelial dystrophy
  • Focus Therapeutic Use

Most Recent Events

  • 01 Jul 2021 Primary endpoint has been met (Change in central corneal thickness from baseline to 1 month and from baseline to 3 months after randomization) , according to Results published in the American Journal of Ophthalmology
  • 01 Jul 2021 Results published in the American Journal of Ophthalmology
  • 02 Jul 2020 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top